Trellis Bioscience Raises $10M

South San Francisco-based Trellis Bioscience has raised $10M in a Series B funding, the firm said Tuesday. The round of funding came from Novartis Bioventures Ltd., which led the round. Other investors included Pac-Link Bio Venture Investment Corporation, Sagamore Bioventures LLC, Easton-Hunt Capital Partners, LP and Morgenthaler Partners VII LP. As part of the funding, Markus Goebel of Novartis Bioventures will join the firm's board. Trellis is developing antibodies for the treatment of infectious disease and oncology. More information »